Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis

Cuiling Qi, Qin Zhou, Bin Li, Yang Yang, Liu Cao, Yuxiang Ye, Jiangchao Li, Yi Ding, Huiping Wang, Jintao Wang, Xiaodong He, Qianqian Zhang, Tian Lan, Kenneth Ka Ho Lee, Weidong Li, Xiaoyu Song, Jia Zhou, Xuesong Yang, Lijing Wang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Angiogenesis is involved in the development, progression and metastasis of various human cancers. Herein, we report the discovery of glipizide, a widely used drug for type 2 diabetes mellitus, as a promising anticancer agent through the inhibition of tumor angiogenesis. By high-throughput screening (HTS) of an FDA approved drug library utilizing our in vivo chick embryo chorioallantoic membrane (CAM) and yolk sac membrane (YSM) models, glipizide has been identified to significantly inhibit blood vessel formation and development. Moreover, glipizide was found to suppress tumor angiogenesis, tumor growth and metastasis using xenograft tumor and MMTV-PyMT transgenic mouse models. We further revealed that the anticancer capability of glipizide is not attributed to its antiproliferative effects, which are not significant against various human cancer cell lines. To investigate whether its anticancer efficacy is associated with the glucose level alteration induced by glipizide application, glimepiride, another medium to long-acting sulfonylurea antidiabetic drug in the same class, was employed for the comparison studies in the same fashion. Interestingly, glimepiride has demonstrated no significant impact on the tumor growth and metastasis, indicating that the anticancer effects of glipizide is not ascribed to its antidiabetic properties. Furthermore, glipizide suppresses endothelial cell migration and the formation of tubular structures, thereby inhibiting angiogenesis by up-regulating the expression of natriuretic peptide receptor A. These findings uncover a novel mechanism of glipizide as a potential cancer therapy, and also for the first time, provide direct evidence to support that treatment with glipizide may reduce the cancer risk for diabetic patients.

Original languageEnglish (US)
Pages (from-to)9966-9979
Number of pages14
JournalOncotarget
Volume5
Issue number20
StatePublished - 2014

Fingerprint

Glipizide
Hypoglycemic Agents
Neoplasm Metastasis
Growth
glimepiride
Neoplasms
Chorioallantoic Membrane
Yolk Sac
Chick Embryo
Heterografts
Pharmaceutical Preparations
Antineoplastic Agents
Type 2 Diabetes Mellitus
Transgenic Mice
Cell Movement
Blood Vessels
Endothelial Cells

Keywords

  • Anticancer
  • Glipizide
  • Metastasis
  • Natriuretic peptide receptor A
  • Tumor angiogenesis

ASJC Scopus subject areas

  • Oncology

Cite this

Qi, C., Zhou, Q., Li, B., Yang, Y., Cao, L., Ye, Y., ... Wang, L. (2014). Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis. Oncotarget, 5(20), 9966-9979.

Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis. / Qi, Cuiling; Zhou, Qin; Li, Bin; Yang, Yang; Cao, Liu; Ye, Yuxiang; Li, Jiangchao; Ding, Yi; Wang, Huiping; Wang, Jintao; He, Xiaodong; Zhang, Qianqian; Lan, Tian; Lee, Kenneth Ka Ho; Li, Weidong; Song, Xiaoyu; Zhou, Jia; Yang, Xuesong; Wang, Lijing.

In: Oncotarget, Vol. 5, No. 20, 2014, p. 9966-9979.

Research output: Contribution to journalArticle

Qi, C, Zhou, Q, Li, B, Yang, Y, Cao, L, Ye, Y, Li, J, Ding, Y, Wang, H, Wang, J, He, X, Zhang, Q, Lan, T, Lee, KKH, Li, W, Song, X, Zhou, J, Yang, X & Wang, L 2014, 'Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis', Oncotarget, vol. 5, no. 20, pp. 9966-9979.
Qi C, Zhou Q, Li B, Yang Y, Cao L, Ye Y et al. Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis. Oncotarget. 2014;5(20):9966-9979.
Qi, Cuiling ; Zhou, Qin ; Li, Bin ; Yang, Yang ; Cao, Liu ; Ye, Yuxiang ; Li, Jiangchao ; Ding, Yi ; Wang, Huiping ; Wang, Jintao ; He, Xiaodong ; Zhang, Qianqian ; Lan, Tian ; Lee, Kenneth Ka Ho ; Li, Weidong ; Song, Xiaoyu ; Zhou, Jia ; Yang, Xuesong ; Wang, Lijing. / Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis. In: Oncotarget. 2014 ; Vol. 5, No. 20. pp. 9966-9979.
@article{2c4fb8ee850d4357b2378b3b700a3e67,
title = "Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis",
abstract = "Angiogenesis is involved in the development, progression and metastasis of various human cancers. Herein, we report the discovery of glipizide, a widely used drug for type 2 diabetes mellitus, as a promising anticancer agent through the inhibition of tumor angiogenesis. By high-throughput screening (HTS) of an FDA approved drug library utilizing our in vivo chick embryo chorioallantoic membrane (CAM) and yolk sac membrane (YSM) models, glipizide has been identified to significantly inhibit blood vessel formation and development. Moreover, glipizide was found to suppress tumor angiogenesis, tumor growth and metastasis using xenograft tumor and MMTV-PyMT transgenic mouse models. We further revealed that the anticancer capability of glipizide is not attributed to its antiproliferative effects, which are not significant against various human cancer cell lines. To investigate whether its anticancer efficacy is associated with the glucose level alteration induced by glipizide application, glimepiride, another medium to long-acting sulfonylurea antidiabetic drug in the same class, was employed for the comparison studies in the same fashion. Interestingly, glimepiride has demonstrated no significant impact on the tumor growth and metastasis, indicating that the anticancer effects of glipizide is not ascribed to its antidiabetic properties. Furthermore, glipizide suppresses endothelial cell migration and the formation of tubular structures, thereby inhibiting angiogenesis by up-regulating the expression of natriuretic peptide receptor A. These findings uncover a novel mechanism of glipizide as a potential cancer therapy, and also for the first time, provide direct evidence to support that treatment with glipizide may reduce the cancer risk for diabetic patients.",
keywords = "Anticancer, Glipizide, Metastasis, Natriuretic peptide receptor A, Tumor angiogenesis",
author = "Cuiling Qi and Qin Zhou and Bin Li and Yang Yang and Liu Cao and Yuxiang Ye and Jiangchao Li and Yi Ding and Huiping Wang and Jintao Wang and Xiaodong He and Qianqian Zhang and Tian Lan and Lee, {Kenneth Ka Ho} and Weidong Li and Xiaoyu Song and Jia Zhou and Xuesong Yang and Lijing Wang",
year = "2014",
language = "English (US)",
volume = "5",
pages = "9966--9979",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "20",

}

TY - JOUR

T1 - Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis

AU - Qi, Cuiling

AU - Zhou, Qin

AU - Li, Bin

AU - Yang, Yang

AU - Cao, Liu

AU - Ye, Yuxiang

AU - Li, Jiangchao

AU - Ding, Yi

AU - Wang, Huiping

AU - Wang, Jintao

AU - He, Xiaodong

AU - Zhang, Qianqian

AU - Lan, Tian

AU - Lee, Kenneth Ka Ho

AU - Li, Weidong

AU - Song, Xiaoyu

AU - Zhou, Jia

AU - Yang, Xuesong

AU - Wang, Lijing

PY - 2014

Y1 - 2014

N2 - Angiogenesis is involved in the development, progression and metastasis of various human cancers. Herein, we report the discovery of glipizide, a widely used drug for type 2 diabetes mellitus, as a promising anticancer agent through the inhibition of tumor angiogenesis. By high-throughput screening (HTS) of an FDA approved drug library utilizing our in vivo chick embryo chorioallantoic membrane (CAM) and yolk sac membrane (YSM) models, glipizide has been identified to significantly inhibit blood vessel formation and development. Moreover, glipizide was found to suppress tumor angiogenesis, tumor growth and metastasis using xenograft tumor and MMTV-PyMT transgenic mouse models. We further revealed that the anticancer capability of glipizide is not attributed to its antiproliferative effects, which are not significant against various human cancer cell lines. To investigate whether its anticancer efficacy is associated with the glucose level alteration induced by glipizide application, glimepiride, another medium to long-acting sulfonylurea antidiabetic drug in the same class, was employed for the comparison studies in the same fashion. Interestingly, glimepiride has demonstrated no significant impact on the tumor growth and metastasis, indicating that the anticancer effects of glipizide is not ascribed to its antidiabetic properties. Furthermore, glipizide suppresses endothelial cell migration and the formation of tubular structures, thereby inhibiting angiogenesis by up-regulating the expression of natriuretic peptide receptor A. These findings uncover a novel mechanism of glipizide as a potential cancer therapy, and also for the first time, provide direct evidence to support that treatment with glipizide may reduce the cancer risk for diabetic patients.

AB - Angiogenesis is involved in the development, progression and metastasis of various human cancers. Herein, we report the discovery of glipizide, a widely used drug for type 2 diabetes mellitus, as a promising anticancer agent through the inhibition of tumor angiogenesis. By high-throughput screening (HTS) of an FDA approved drug library utilizing our in vivo chick embryo chorioallantoic membrane (CAM) and yolk sac membrane (YSM) models, glipizide has been identified to significantly inhibit blood vessel formation and development. Moreover, glipizide was found to suppress tumor angiogenesis, tumor growth and metastasis using xenograft tumor and MMTV-PyMT transgenic mouse models. We further revealed that the anticancer capability of glipizide is not attributed to its antiproliferative effects, which are not significant against various human cancer cell lines. To investigate whether its anticancer efficacy is associated with the glucose level alteration induced by glipizide application, glimepiride, another medium to long-acting sulfonylurea antidiabetic drug in the same class, was employed for the comparison studies in the same fashion. Interestingly, glimepiride has demonstrated no significant impact on the tumor growth and metastasis, indicating that the anticancer effects of glipizide is not ascribed to its antidiabetic properties. Furthermore, glipizide suppresses endothelial cell migration and the formation of tubular structures, thereby inhibiting angiogenesis by up-regulating the expression of natriuretic peptide receptor A. These findings uncover a novel mechanism of glipizide as a potential cancer therapy, and also for the first time, provide direct evidence to support that treatment with glipizide may reduce the cancer risk for diabetic patients.

KW - Anticancer

KW - Glipizide

KW - Metastasis

KW - Natriuretic peptide receptor A

KW - Tumor angiogenesis

UR - http://www.scopus.com/inward/record.url?scp=84924946354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924946354&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 9966

EP - 9979

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 20

ER -